These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 15365145)
1. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Enting RH; Demopoulos A; DeAngelis LM; Abrey LE Neurology; 2004 Sep; 63(5):901-3. PubMed ID: 15365145 [TBL] [Abstract][Full Text] [Related]
2. Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide. Pitini V; Baldari S; Altavilla G; Arrigo C; Naro C; Perniciaro F J Neurooncol; 2007 Jul; 83(3):291-3. PubMed ID: 17245621 [TBL] [Abstract][Full Text] [Related]
3. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567 [TBL] [Abstract][Full Text] [Related]
4. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Wong ET; Tishler R; Barron L; Wu JK Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999 [TBL] [Abstract][Full Text] [Related]
5. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma. Murakami M; Fujimaki T; Asano S; Nakaguchi H; Yamada SM; Hoya K; Yamazaki K; Ishida Y; Matsuno A Yonsei Med J; 2011 Nov; 52(6):1031-4. PubMed ID: 22028172 [TBL] [Abstract][Full Text] [Related]
7. A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide. Wong SF; Gan HK; Cher L J Clin Neurosci; 2012 Nov; 19(11):1501-5. PubMed ID: 22995759 [TBL] [Abstract][Full Text] [Related]
8. Complete response to temozolomide treatment in an elderly patient with recurrent primary central nervous system lymphoma--case report. Makino K; Nakamura H; Kudo M; Takeshima H; Kuratsu J Neurol Med Chir (Tokyo); 2007 May; 47(5):229-32. PubMed ID: 17527051 [TBL] [Abstract][Full Text] [Related]
9. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Wong ET Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455 [No Abstract] [Full Text] [Related]
10. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Santisteban M; Nieto Y; De la Cruz S; Aristu J; Zubieta JL; Fernández Hidalgo O Clin Transl Oncol; 2007 Jul; 9(7):465-7. PubMed ID: 17652061 [TBL] [Abstract][Full Text] [Related]
11. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634 [TBL] [Abstract][Full Text] [Related]
12. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. Chamberlain MC J Neurooncol; 2014 May; 118(1):155-62. PubMed ID: 24584709 [TBL] [Abstract][Full Text] [Related]
15. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. Reni M; Ferreri AJ; Landoni C; Villa E J Natl Cancer Inst; 2000 Apr; 92(7):575-6. PubMed ID: 10749917 [No Abstract] [Full Text] [Related]
16. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989 [TBL] [Abstract][Full Text] [Related]
17. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment]. Yamanaka R Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942 [TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A; Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234 [TBL] [Abstract][Full Text] [Related]
19. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial. Chamberlain MC; Colman H; Kim BT; Raizer J J Neurooncol; 2017 Feb; 131(3):507-516. PubMed ID: 28204914 [TBL] [Abstract][Full Text] [Related]
20. Rituximab maintenance therapy in central nervous system lymphoma? Murawski N; Pfreundschuh M Leuk Lymphoma; 2009 Oct; 50(10):1555-6. PubMed ID: 19757314 [No Abstract] [Full Text] [Related] [Next] [New Search]